We would love to hear your thoughts about our site and services, please take our survey here.
How has it increased? Deluded.
Only the CEO gets paid the most and the rest don't get much at all. I would imagine they will get share options moving forward with a lower salary so would need to deliver first. We don't have a second CEO claiming a salary at the moment so talking nonsense as usual.
Official information below and not Porky's nonsense. He lost it all on 4D so nothing will change with him ever.
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
Expenses will go up over the years. Natural and for a biotech it is very low.
Revenue will come in through the lab. No question about that and still every chance 201 completes very soon.
Therefore Q2 2025 is likely to be significantly extended.
Agree the company would have been busted without Suzy and Kevin but they made a mess of it with 201 and therefore the share price. Hopefully they can seal the deal with 201 shortly. That will really move the share price big now.
Kevin has stayed to see it through and I suspect Suzy will step down on a high.
She had no choice because otherwise shareholders wanted Kevin gone and then gone after Suzy as well. A combination of experience of shareholders and experience board members is positive.
They have cash until Q2 2025 and with revenue coming in that should be extended. I think 201 will complete so a good cash runway.
You need experience so no choice but to keep him. We have a shareholder on the board and changes as requested.
It is a combination of both experience and shareholder interests which should work. It would have been better had it been Adam before he got turned down.
I am sure if new investors were buying here they would be happy with 10p. One can then say they are only about 600% from the highs from 10p.
Not a valid point. EUDA market cap $40 million and rising.
It shows the value on offer and potential upside from here when 201 completes. We were stable in 40s with a peak at 65p with LOI and no CLX, Imogen or lab so at 3p a steal and still very likely to complete shortly.
I have a low average anyway so it matters now. I was massively in profit now but it matters now.
Expecting merger to complete this month and a strong recovery.
Again you fail to understand the absolute basics and if people were really honest they would know it.
So you talk about 9 evaluations. If these were outsourced to external labs that would be a very significant extra cost compared to bringing them into your own lab times that by 9. Also bringing them internally gives control of timings and allows further testing using some of the agreed collaborations they have therefore giving better chances of positive outcomes.
I don't know as much about Imogen and the biobank business but I doubt you do either but what they are saying is that it will help generate significant revenue soon. The lab alone is not likely to do that. If that is the case then all we can do is wait and see. Valirx is not a lab business just are looking for side revenue and mainly to help progress the evaluation projects.
The only part I would agree with is that they should not spend more on other assets for a long while. Keep spending down until a real deal so that actually means bringing in 3 quality projects a year until they strike a deal. What you don't want is to be funding numerous preclinical projects at the same time at a low share price or without a deal with revenue because then the costs will blow.
You cannot counter my point instead of turning to a post many years back. Weak..
Share price is dictated by market perception of which 0% on this board really understand the strategy fully therefore a false price at the current time.
The only way to fix the issue is to get 201 over the line soon or a deal for CLX or another deal in the next year with cash payments and higher share price plus some decent lab contracts.
No board changes can divert away from that fact and change the situation. It needs experience and knowledge of this industry.
Bloody clueless as it gets.
9 evaluations will cost. So if they pass how will they fund pre clinical testing with zero cash and burning less than 1.5 million.If 3/9 pass you have to fund those. If all 9 fail that will drop the SP and confidence. Based on this they will likely need at least 5 million per year if you bring so many projects in maybe more.
You can only bring in quality products otherwise it is a waste of time and money. The project and terms have to be right some will want more payments to take it on. It takes time to go over the science and negotiate terms for the right projects.
It is all wishful thinking without actually understanding the costs involved. VAL needs 201 to complete for a higher share price and lower dilutions as well as extra money.
Your approach is a bust approach with no understanding of costs, strategy and value adding news.
She could which is why I don't support the requisition at this point as removing Kevin now could lead to Suzy leaving as well.
Those suggested to replace no doubt want Suzy to remain as they need someone that can guild them without any experience in this field but somehow it will not work.
Without all this instability I do think 201 will complete very soon and we will recover at least to double digits with other news coming as well. A completely new BOD just means more mistakes with a lack of experience and the cycle starts again. Rinse and repeat with mistakes after mistakes and an even lower placing.
Why would it as you stated many times that you are not invested.
The Valirx Twitter account is still up so it means nothing
On a positive note EUDA finished up 16% and rumour is that the merger will complete soon.
why do you care so much????
with so much projects ongoing including 201, at 5 million market cap it will not take much to take this to 10/15 million comfortably. it would be a right **** up if we are where we are in the coming weeks.
buy low and sell high applies now.